Bridgeway Capital Management, LLC Gilead Sciences, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $37.7 Million - $42.3 Million	-603,600 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $11.1 Million - $14.5 Million	-183,200 Reduced 23.28%	603,600 $37.8 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $21.2 Million - $23.5 Million	-297,750 Reduced 27.45%	786,800 $60.7 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $1.31 Million - $1.53 Million	20,175 Added 1.9%	1,084,550 $76.8 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $1.5 Million - $1.83 Million	-20,600 Reduced 1.9%	1,064,375 $80.2 Million

Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $23.8 Million - $28 Million	334,710 Added 44.61%	1,084,975 $77.7 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $54.1 Million - $64.1 Million	750,265	750,265 $60.8 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $84.9B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.